ArticleEncephalitis (Seoul, Korea)2025
Anti-N-methyl-ᴅ-aspartate receptor encephalitis in India: a case series and review of the literature.
Article in Encephalitis (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Anti-N-methyl-ᴅ-aspartate receptor encephalitis (NMDARE) is an autoimmune disorder of the central nervous system characterized by subacute- onset neurocognitive disorders, seizures, movement disorders, and prominent neuropsychiatric features affecting young adults. This case series describes the clinical profile, neuroimaging features, and outcomes in NMDARE patients and attempts to compare its findings with previously published studies in an Indian setting. Methods: All consecutive patients diagnosed with definite NMDARE over a 2-year period were evaluated and followed up with. A comprehensive literature review was conducted in PubMed, Scopus, Embase, and Google Scholar, covering studies published up to January 2025. Results: The case series included six patients (four females) aged 10-19 years presenting with super-refractory status epilepticus, dystonia, rubral tremors, and psychiatric symptoms. Tumor screening was negative in all cases. Magnetic resonance imaging of the brain revealed white matter hyperintensities in the medial temporal lobe, periventricular white matter, basal ganglia, and midbrain. Electroencephalogram abnormalities included diffuse slowing, extreme delta brush, and epileptiform discharges. Patients responded to high-dose intravenous methylprednisolone and intravenous immunoglobulin in most cases, with rituximab and cyclophosphamide administered successfully in refractory cases. Our review of Indian literature on NMDARE revealed 60 studies (115 patients), among which 48 case reports were excluded and 12 clinical studies and case series were included. Included patients were aged 2-29 years and mostly female, with similar clinical and imaging profiles to our population and a comparable low yield of tumor screening. Prognosis was good with immunotherapy, with few fatality reports. Conclusion: NMDARE patients present with protean clinical manifestations and difficult diagnostic and therapeutic challenges, resulting in an unclear prognosis. Early recognition, aggressive immunotherapy, and regular follow-up are key to better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.